2. Search Result
Search Result
Pathways Recommended: Stem Cell/Wnt Cell Cycle/DNA Damage
Results for "

cancer cell surfaces

" in MedChemExpress (MCE) Product Catalog:

129

Inhibitors & Agonists

1

Screening Libraries

7

Fluorescent Dyes

19

Biochemical Assay Reagents

11

Peptides

34

Inhibitory Antibodies

9

Natural
Products

6

Click Chemistry

10

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P99045
    Sacituzumab
    4 Publications Verification

    HRS7; hRS7

    		 ADC Antibody TROP2 Cancer
    Sacituzumab is a humanized IgG1 monoclonal antibody targeting Trophoblast cell surface antigen 2 (TROP2). Sacituzumab demonstrates a lack of antitumor effects alone and does not inhibit the function of TROP-2 during tumor metastasis, binding to the linear epitopes of TROP-2 protein. Sacituzumab can be used for the synthesis of antibody-drug conjugates (ADC) drug Sacituzumab govitecan (HY-132254). Sacituzumab govitecan can be used in the field of triple-negative breast cancer .
    Sacituzumab
  • HY-B0633A
    Hyaluronic acid
    15+ Cited Publications

    Hyaluronan; Hyaluronate

    		 Endogenous Metabolite Bacterial Akt PI3K Infection Neurological Disease Inflammation/Immunology Cancer
    Hyaluronic acid is a biopolymer composed of repeating units of disaccharides with various applications. Hyaluronic acid is a major component of the extracellular matrix (ECM). Hyaluronic acid is synthesized at the plasma membrane. Increased hyaluronic acid levels are associated with tumor cell growth, adhesion, migration, invasion and angiogenesis in digestive cancers. Hyaluronic acid participates in tissue remodeling and rapid cell proliferation in some physiological processes including embryonic morphogenesis and wound-healing. Hyaluronic acid activates the PI3K-Akt signaling. Hyaluronic acid acts as a regulator of cancer-associated lymphangiogenesis. Hyaluronic acid also enhances cell invasion and angiogenesis by promoting proteolytic MMP-9 binding to cell surface or stimulating MMP-9 binding to cell surface. Hyaluronic acid can be used as drug delivery for sodium butyrate to improve the anti-proliferative activity on breast cancer cell line. Hyaluronic acid can be studied in joint diseases, wound healing and cancer .
    Hyaluronic acid
  • HY-B0633
    Hyaluronic acid sodium
    Maximum Cited Publications
    18 Publications Verification

    Sodium hyaluronate

    		 Endogenous Metabolite Bacterial PI3K Akt Inflammation/Immunology Cancer
    Hyaluronic acid sodium (Sodium hyaluronate) is a biopolymer composed of repeating units of disaccharides with various applications. Hyaluronic acid sodium is a major component of the extracellular matrix (ECM). Hyaluronic acid sodium is synthesized at the plasma membrane. Increased hyaluronic acid sodium levels are associated with tumor cell growth, adhesion, migration, invasion and angiogenesis in digestive cancers. Hyaluronic acid sodium participates in tissue remodeling and rapid cell proliferation in some physiological processes including embryonic morphogenesis and wound-healing. Hyaluronic acid sodium activates the PI3K-Akt signaling. Hyaluronic acid sodium acts as a regulator of cancer-associated lymphangiogenesis. Hyaluronic acid sodium also enhances cell invasion and angiogenesis by promoting proteolytic MMP-9 binding to cell surface or stimulating MMP-9 binding to cell surface. Hyaluronic acid sodium can be used as drug delivery for sodium butyrate to improve the anti-proliferative activity on breast cancer cell line. Hyaluronic acid sodium can be studied in joint diseases, wound healing and cancer .
    Hyaluronic acid sodium
  • HY-P0023
    Cyclo(-RGDfK)
    25+ Cited Publications

    		 Integrin Cancer
    Cyclo(-RGDfK) is a potent and selective inhibitor of the αvβ3 integrin, with an IC50 of 0.94 nM. Cyclo(-RGDfK) potently targets tumor microvasculature and cancer cells through the specific binding to the αvβ3 integrin on the cell surface .
    Cyclo(-RGDfK)
  • HY-P99843
    Datopotamab
    1 Publications Verification

    		 TROP2 ADC Antibody Cancer
    Datopotamab (CDP7657) is a humanized anti trophoblast cell surface antigen 2 (TROP2) antibody. Datopotamab can generate antibody drug conjugates (ADC) (HY-141598) with DNA topoisomerase I inhibitor Deruxtecan (HY-13631E). Datopotamab can be used in the study of triple negative breast cancer and non-small cell lung cancer .
    Datopotamab
  • HY-113016
    Elaidic acid
    4 Publications Verification

    		 Apoptosis Wnt ERK Bacterial Interleukin Related Infection Metabolic Disease Cancer
    Elaidic acid is an orally active trans fatty acid. Elaidic acid enhances the stemness of colorectal cancer cells by activating the Wnt/ERK1/2 pathway, thereby promoting cell proliferation, invasion and metastasis, and inhibiting apoptosis. Elaidic acid also inhibits the growth of Lactobacillus and alters the cell surface hydrophobicity of Lactobacillus. Elaidic acid reduces basal 2-deoxyglucose uptake in muscle cells and adipocytes. Elaidic acid can be used in research on colorectal cancer, insulin and other related areas .
    Elaidic acid
  • HY-P99391
    Telisotuzumab

    ABT-700; ABBV-400 Antibody

    		 c-Met/HGFR Apoptosis Cancer
    Telisotuzumab (ABT-700) is a bivalent humanized IgG1 anti-c-Met monoclonal antibody. Telisotuzumab binds cellular c-Met and disrupts its productive dimerization and activation induced by HGF or by the high density of c-Met on the cell surface independent of ligand. Telisotuzumab induces apoptosis. Telisotuzumab can be used for the study of cancers harboring amplified MET, such as gastric and lung cancers .
    Telisotuzumab
  • HY-161111
    KVS0001

    		Ser/Thr Kinase Cancer
    KVS0001 is a selective SMG1 inhibitor. KVS0001 elevates the expression of transcripts and proteins resulting from truncating mutations. KVS0001 increased the presentation of immune-targetable HLA class I-associated peptides from nonsense-mediated decay (NMD)-downregulated proteins on the surface of cancer cells. KVS0001 exerts anti-tumor properties and can be studied in research for NMD-related diseases, including cancer and inherited diseases .
    KVS0001
  • HY-P0023A
    Cyclo(-RGDfK) TFA
    25+ Cited Publications

    		 Integrin Cancer
    Cyclo(-RGDfK) TFA is a potent and selective inhibitor of the αvβ3 integrin, with an IC50 of 0.94 nM . Cyclo(-RGDfK) TFA potently targets tumor microvasculature and cancer cells through the specific binding to the αvβ3 integrin on the cell surface .
    Cyclo(-RGDfK) TFA
  • HY-164734
    Raludotatug Deruxtecan

    R-DXd; DS-6000

    		 Antibody-Drug Conjugates (ADCs) Cancer
    Raludotatug Deruxtecan is an antibody-drug conjugate targeting CDH6, with an EC50 of 64.7 ng/mL in humans, 70.4 ng/mL in cynomolgus monkeys, and 228 ng/mL in mice. Raludotatug Deruxtecan specifically binds to CDH6 on the surface of cancer cells, triggers lysosomal internalization, and releases the DXd payload that inhibits TOP1. Raludotatug Deruxtecan induces DNA damage, Chk1 phosphorylation, caspase-3 cleavage, apoptosis, and bystander cell death. Raludotatug Deruxtecan is applicable to research related to serous ovarian cancer and renal cell carcinoma .
    Raludotatug Deruxtecan
  • HY-P9933
    Dinutuximab

    APN-311; Ch14.18; MAb-14.18

    		 Apoptosis PERK mTOR Cancer
    Dinutuximab (APN-311) is a chimeric human-mouse anti-GD2 monoclonal antibody. Dinutuximab can bind to GD2 on the cell surface, triggering antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity, and promoting tumor regression. Dinutuximab can inhibit the growth, invasion, and migration and induce apoptosis of tumor cells. Dinutuximab can be used in the research of tumors such as neuroblastoma and breast cancer .
    Dinutuximab
  • HY-P99011
    Cibisatamab
    2 Publications Verification

    		 CD3 Cancer
    Cibisatamab, a T cell bispecific antibody, binds Carcino-Embryonic Antigen (CEA) on cancer cells and CD3 on T cells. Cibisatamab triggers T cell killing of cancer cell lines expressing moderate to high levels of CEA at the cell surface. Cibisatamab can be used for colorectal cancer research .
    Cibisatamab
  • HY-125474
    Carrageenan
    1 Publications Verification

    		 Environmental Pollutants HIV HSV Infection Cancer
    Carrageenan is an antiviral and anticancer agent. Carrageenan inhibits herpes simplex virus (HSV), HIV, and hepatitis A virus (HAV) by directly binding to the viral capsid to block the attachment of viruses such as HPV to HSPG factors on the cell surface. Carrageenan delays and arrests cell cycle progression, exhibits cytotoxicity against HeLa cancer cells, and can be applied to studies related to cervical cancer, genital warts, hepatitis A, and other conditions. Carrageenan also induces acute non-immune inflammation, triggers a three-phase inflammatory response involving the release of multiple proinflammatory mediators, and causes persistent edema, hyperalgesia, and neutrophil recruitment in mice .
    Carrageenan
  • HY-148118A
    Tri-GalNAc(OAc)3 TFA

    		LYTACs Cancer
    Tri-GalNAc(OAc)3 TFA is a trivalent N-acetylgalactosamine (GalNAc) derivative that can be used to synthesize GalNAc-LYTAC. Tri-GalNAc is a specific ligand targeting the asialoglycoprotein receptor (ASGPR), mediating the endocytosis and transport of cell surface proteins (such as EGFR, HER2) to lysosomes for degradation by lysosomal targeting chimeras (LYTACs). Tri-GalNAc significantly reduces the level of target proteins and inhibits downstream signaling pathways (such as EGFR-mediated Akt and MAPK signals). Tri-GalNAc(OAc)3 TFA can be used for hepatocyte targeting studies, and can degrade carcinogenic membrane proteins and inhibit tumor cell proliferation in liver cancer cell models .
    Tri-GalNAc(OAc)3 TFA
  • HY-P99045A
    Sacituzumab (powder)

    		ADC Antibody TROP2 Cancer
    Sacituzumab (powder) is a humanized IgG1 monoclonal antibody targeting Trophoblast cell surface antigen 2 (TROP2). Sacituzumab (powder) demonstrates a lack of antitumor effects alone and does not inhibit the function of TROP-2 during tumor metastasis, binding to the linear epitopes of TROP-2 protein. Sacituzumab (powder) can be used for the synthesis of antibody-drug conjugates (ADC) drug Sacituzumab govitecan (HY-132254). Sacituzumab govitecan can be used in the field of triple-negative breast cancer .
    Sacituzumab (powder)
  • HY-172464
    DSPE-PEG2000-cRGD

    		Liposome Integrin Cancer
    DSPE-PEG2000-cRGD is a PEG compound which composed of DSPE and an αvβ3 targeting peptide (cRGD). cRGD peptide can specifically bind to αvβ3 on the surface of many cancer cells and neovascular cells. DSPE-PEG2000-cRGD can be used for drug delivery .
    DSPE-PEG2000-cRGD
  • HY-W782083
    p-SCN-Bn-NOTA trihydrochloride

    		Biochemical Assay Reagents Radionuclide-Drug Conjugates (RDCs) Bombesin Receptor EGFR Cancer
    p-SCN-Bn-NOTA trihydrochloride is a macrocyclic chelator. p-SCN-Bn-NOTA trihydrochloride can be covalently coupled to molecules such as peptides through the thiocyanate group to form hexacoordinate copper (such as 64Cu) complexes. p-SCN-Bn-NOTA trihydrochloride specifically binds to GRPR or EGFR highly expressed on the surface of tumor cells, mediating tumor enrichment of radioactive probes. p-SCN-Bn-NOTA trihydrochloride can be used to study malignant tumors expressing GRPR or EGFR, such as prostate cancer and colorectal cancer .
    p-SCN-Bn-NOTA trihydrochloride
  • HY-134884
    INCB086550
    2 Publications Verification

    PD-1/PD-L1-IN-8

    		 PD-1/PD-L1 Cancer
    INCB086550 is a potent, oral, small-molecule PD-L1 inhibitor with IC50s value of 3.1, 4.9 and 1.9 nM for human, cynomolgus, and rat, respectively. INCB086550 promotes the dimerization of cell-surface PD-L1 and induces PD-L1 entry into Golgi vesicles then traffick to the nucleus. INCB086550 can be used for multiple cancers research .
    INCB086550
  • HY-W591424
    m-PEG2000-NHS ester

    mPEG2000-SC; mPEG2000-Succinimidyl ester

    		 Biochemical Assay Reagents MMP Cancer
    m-PEG2000-NHS ester (mPEG2000-SC) is a reagent with both cell adhesion inhibition and peptide conjugation functions. The NHS ester group of m-PEG2000-NHS ester forms stable amide bonds with primary amine-containing molecules (e.g., the N-terminus of MMP-2-cleavable octapeptide) to generate mPEG-peptide intermediates for liposome surface modification. When m-PEG2000-NHS ester is immobilized on a cystamine-modified gold surface, it can construct an in vitro model for cell adhesion kinetic studies, and higher PEG density and thicker layers correlate with lower cell adhesion rates. m-PEG2000-NHS ester can synthesize MMP-2-responsive PEGylated lipid conjugates to achieve MMP-triggered dePEGylation in the tumor microenvironment. m-PEG2000-NHS ester can be used in studies related to colon cancer and other conditions .
    m-PEG2000-NHS ester
  • HY-P99682
    Ladiratuzumab

    hLIV22

    		 ADC Antibody Cancer
    Ladiratuzumab (hLIV22) is a humanized monoclonal antibody against zinc transporter LIV-1/ZIP6. Ladiratuzumab is conjugated to MMAE (HY-15162) via a cleavable dipeptide linker to synthesize an antibody-drug conjugate (ADC) Ladiratuzumab vedotin (HY-P99683). Ladiratuzumab vedotin selectively targets LIV-1 protein overexpressed on the surface of tumor cells, enters cells through antibody-mediated receptor endocytosis, releases MMAE to inhibit microtubule polymerization, and kills adjacent tumor cells with a bystander effect. Ladiratuzumab can be used in the study of solid tumors such as metastatic triple-negative breast cancer (mTNBC) .
    Ladiratuzumab
  • HY-B0633I
    Hyaluronic acid sodium (MW 800kDa)

    		Endogenous Metabolite Bacterial PI3K Akt Inflammation/Immunology Cancer
    Hyaluronic acid sodium (MW 800kDa) is a biopolymer composed of repeating units of disaccharides with various applications. Hyaluronic acid sodium is a major component of the extracellular matrix (ECM). Hyaluronic acid sodium is synthesized at the plasma membrane. Increased hyaluronic acid sodium levels are associated with tumor cell growth, adhesion, migration, invasion and angiogenesis in digestive cancers. Hyaluronic acid sodium participates in tissue remodeling and rapid cell proliferation in some physiological processes including embryonic morphogenesis and wound-healing. Hyaluronic acid sodium activates the PI3K-Akt signaling. Hyaluronic acid sodium acts as a regulator of cancer-associated lymphangiogenesis. Hyaluronic acid sodium also enhances cell invasion and angiogenesis by promoting proteolytic MMP-9 binding to cell surface or stimulating MMP-9 binding to cell surface. Hyaluronic acid sodium can be used as drug delivery for sodium butyrate to improve the anti-proliferative activity on breast cancer cell line. Hyaluronic acid sodium can be studied in joint diseases, wound healing and cancer .
    Hyaluronic acid sodium (MW 800kDa)
  • HY-30170
    N-Methylphenethylamine

    		Endogenous Metabolite Adrenergic Receptor Neurological Disease
    N-Methylphenethylamine is an indirectly acting sympathomimetic amine that is formed via PNMT-catalyzed N-methylation of phenethylamine (PEA) in the human body. N-Methylphenethylamine exhibits affinity for β-adrenergic receptors on the surface of cancer cells or bacterial cells. N-Methylphenethylamine can be used for neurotransmitter research or as a pharmaceutical intermediate .
    N-Methylphenethylamine
  • HY-128784
    PK11007

    		MDM-2/p53 Reactive Oxygen Species (ROS) Cancer
    PK11007 is a mild thiol alkylator with anticancer activity. PK11007 stabilizes p53 via selective alkylation of two surface-exposed cysteines without compromising its DNA binding activity. PK11007 induces mutant p53 cancer cell death by increasing reactive oxygen species (ROS) levels .
    PK11007
  • HY-P99157
    Omburtamab

    		CD276/B7-H3 Cancer
    Omburtamab is a humanized monoclonal antibody targeting B7-H3 (CD276). Omburtamab selectively binds to B7-H3 highly expressed on the surface of tumor cells and activates anti-tumor immune responses mediated by T cells and natural killer (NK) cells. Omburtamab can promote the specific infiltration of CAR-T cells into tumors, enhance the killing function of NK cells through the CD16 signaling pathway, and regulate tumor cell glucose metabolism (such as inhibiting the Warburg effect). Omburtamab has the potential to inhibit solid tumors such as non-small cell lung cancer (NSCLC) .
    Omburtamab
  • HY-160066
    SYL3C aptamer sodium

    		Transmembrane Glycoprotein Cancer
    SYL3C aptamer sodium is a DNA aptamer that targets epithelial cell adhesion molecule (EpCAM) on the surface of cancer cells. SYL3C aptamer sodium targets a variety of human cancer cell lines including MDA-MB-231, Kato III, HT-29, T47D and SW480. The Kd values of SYL3C aptamer sodium against breast cancer cell line MDA-MB-231 and gastric cancer cell line Kato III are 38 nM and 67 nM, respectively. SYL3C aptamer sodium possesses stability, high binding affinity and selectivity, and can be used for targeted cancer cell imaging and circulating tumor cell detection .
    SYL3C aptamer sodium
  • HY-P1654
    A20FMDV2

    		Integrin Cancer
    A20FMDV2 is a highly selective αvβ6 integrin inhibitor with human IC50 values of 3 nM and binds with at least 1000-fold selectivity over other RGD-binding integrins. A20FMDV2 binds to the integrin’s RGD-binding site, induces rapid integrin internalization, and delays post-internalization integrin recycling to the cell surface. A20FMDV2 can be used for the research of pancreatic cancer, breast cancer, colorectal cancer, ovarian cancer, oral squamous cell carcinoma .
    A20FMDV2
  • HY-NP163A
    Wheat germ agglutinin-AF488

    WGA-AF488

    		 Fluorescent Dye Cancer
    Wheat germ agglutinin-AF488 (WGA-AF488) is a cell membrane-specific staining agent prepared by conjugating wheat germ agglutinin with the Alexa Fluor 488 (HY-D1304) fluorescent dye, and it binds to cell surface glycoproteins with high affinity. Wheat germ agglutinin-AF488 is applied in fluorescence microscopy and confocal imaging techniques, and it can clearly label the membrane structures of various cells including breast cancer cells, enabling high-resolution visual observation. Wheat germ agglutinin-AF488 is used in studies of breast cancer and triple-negative breast cancer to observe cell morphology and membrane dynamic changes .
    Wheat germ agglutinin-AF488
  • HY-159500
    Zopocianine

    OTL-0078; OTL78

    		 PSMA Cancer
    Zopocianine (OTL-0078; OTL78) is a near-infrared optical probe targeting PSMA. Zopocianine binds to PSMA on the surface of PSMA-expressing cells, enters cells via receptor-mediated endocytosis, and accumulates in acidic endosomes. Zopocianine selectively accumulates in PSMA-positive cancer tissues and enables the detection of small tumors, primary prostate tumors, and locoregional metastases. Zopocianine helps achieve negative tumor surgical margins during fluorescence-guided surgery. Zopocianine is applicable to research related to prostate cancer .
    Zopocianine
  • HY-P990690
    Volrustomig

    MEDI-5752

    		 PD-1/PD-L1 CTLA-4 Cancer
    Volrustomig (MEDI-5752) is a human IgG1 κ monoclonal antibody targeting CTLA4/PD1. The isotype control for Volrustomig is Human IgG1 kappa, Isotype Control (HY-P99001). Volrustomig anchors to the surface of T cells by binding PD-1, induces PD-1 internalization and degradation, and preferentially inhibits CTLA-4 on activated PD-1 + T cells. Volrustomig binds to tumor-infiltrating lymphocytes and a subset of PD-1 + B cells, enhances T cell function and IFNγ secretion. Volrustomig reduces the activation of non-tumor-infiltrating lymphocytes and exhibits manageable toxicity. Volrustomig can be used in research on various cancers, such as non-small cell lung cancer, gastric cancer, hepatobiliary cancer, and cervical cancer .
    Volrustomig
  • HY-P99230
    Pinatuzumab

    		Integrin CD22 Cancer
    Pinatuzumab is a humanized monoclonal antibody targeting cell-surface antigen CD22. Pinatuzumab can be used to synthesize antibody-drug conjugate (ADC) such as Pinatuzumab vedotin (HY-141602). Pinatuzumab can be studied in research on cancer such as non-Hodgkin lymphoma. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
    Pinatuzumab
  • HY-N4246
    Bacopaside I

    		Aquaporin PKC Akt PI3K Apoptosis Monoamine Oxidase Pregnane X Receptor (PXR) Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
    Bacopaside I is an orally active aquaporin AQP1 inhibitor and PKC modulator with neuroprotective and anticancer activities. Bacopaside I specifically blocks the water channel and cGMP-gated ion channel activities of AQP1 without affecting AQP4, thereby inhibiting the migration of colon cancer cells expressing AQP1. Bacopaside I activates the Akt pathway by interacting with PI3K, specifically inhibits MAO-A, effectively alleviates neuron necrosis and apoptosis induced by oxygen-glucose deprivation, reduces oxidative stress, and regulates the surface expression of neuroreceptors. When combined with Bacopaside II (HY-N6016), Bacopaside I significantly reduces the viability, proliferation and invasion ability of breast cancer cells, and binds to the pregnane X receptor (PXR). Bacopaside I is applicable to the research of colon cancer, breast cancer, vascular dementia, cerebral ischemia and other related diseases .
    Bacopaside I
  • HY-P990742
    Givastomig

    TJ-CD4B; ABL111; TJ033721

    		 TNF Receptor Claudin Inflammation/Immunology Cancer
    Givastomig (ABL111, TJ033721) is a bispecific antibody (BsAb) inhibitor. Givastomig can specifically binds to Claudin18.2 (CLDN 18.2) on the surface of cancer cells and 4-1BB (CD137, TNFRSF9) on the surface of activated T cells and natural killer (NK) cells. Givastomig is engineered to contain a single Fc-domain mutation (asparagine to alanine) to eliminate Fc-effector function. Givastomig-bound cell lines expressing a range of CLDN18.2 levels with high affinity and induced 4-1BB activation only in the context of CLDN18.2 binding. Givastomig can be used for the study of colon carcinoma .
    Givastomig
  • HY-P2997
    γ-glutamyltransferase, Porcine kidney
    1 Publications Verification

    GGT, Porcine kidney

    		 Endogenous Metabolite Cancer
    γ-glutamyltransferase, Porcine kidney (GGT, Porcine kidney) is an enzyme located on the outer surface of the cell membrane. γ-glutamyltransferase, Porcine kidney maintains the physiological concentration of cytoplasmic glutathione and the cell's defense against oxidative stress by cleaving extracellular glutathione and increasing the availability of amino acids. γ-glutamyltransferase, Porcine kidney is used for pancreatic cancer research .
    γ-glutamyltransferase, Porcine kidney
  • HY-P99242
    Alsevalimab
    1 Publications Verification

    		 CD276/B7-H3 Cancer
    Alsevalimab is a humanized, afucosylated IgG1 monoclonal antibody against B7-H4. Alsevalimab blocks the binding of the B7-H4 protein to the receptors on the surface of T cells, reversing the immunosuppressive state in the tumor microenvironment, thereby activating the killing effect of T cells on cancer cells. Alsevalimab can be used in combination with Pembrolizumab (HY-P9902), and shows good safety profiles .
    Alsevalimab
  • HY-W1123936B
    DBCO-PEG1000-FA

    DBCO-PEG1000-Folate

    		 Folate Receptor (FR) Cancer
    DBCO-PEG1000-FA (DBCO-PEG1000-Folate) is a multifunctional bioconjugation reagent, which is a copolymer of DBCO and Folic acid (FA) (HY-16637) and can target folate receptors (FR). Folate receptors are highly overexpressed on the surface of many cancer cells (such as lung cancer, nasopharyngeal cancer, ovarian cancer, etc.), but exhibit extremely low expression levels in normal tissues. DBCO-PEG-FA can be used for click chemistry conjugation via its DBCO terminal, and thus applies to various bioconjugation and drug delivery applications .
    DBCO-PEG1000-FA
  • HY-P5290
    HYNIC-PSMA

    		Radionuclide-Drug Conjugates (RDCs) PSMA Cancer
    HYNIC-PSMA is a ligand for molecular imaging of tumors. Hynic-psma consists of two components: HYNIC (6-hydrazinonicotinamide) and PSMA (Prostate-Specific Membrane Antigen). HYNIC is a compound used to attach radioactive isotopes to targeted molecules, such as 188Re-HYNIC-PSMA. PSMA is a membrane antigen that is specifically expressed on the surface of prostate cancer cells. HYNIC-PSMA can be used in prostate cancer research . HYNIC-PSMA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    HYNIC-PSMA
  • HY-147007
    β-catenin-IN-3
    1 Publications Verification

    		 β-catenin Wnt CDK Cancer
    β-catenin-IN-3 (Compound C2) is a selective β-catenin inhibitor. β-catenin-IN-3 binds to allosteric site on the surface of β-catenin with K D calculated at 54.96 nM. β-catenin-IN-3 selectively inhibits β-catenin via targeting a cryptic allosteric modulation site, lowers its cellular load. β-catenin-IN-3 significantly reduces viability of β-catenin driven cancer cells, and triggers β-catenin degradation via proteasome system in β-catenin-overexpressing cancer cells .
    β-catenin-IN-3
  • HY-P991742
    LY4101174 Antibody

    15A7.5; ETx-22 Antibody

    		 ADC Antibody Cancer
    LY4101174 Antibody is an ADC antibody. LY4101174 is an antibody-drug conjugate (ADC) that targets the nectin-4 protein present on the surface of certain cancer cells. It can directly deliver a potent chemotherapy agent (Exatecan (HY-13631)) to the tumor site and is used for the study of advanced cancers, such as urothelial carcinoma, triple-negative breast cancer, and non-small cell lung cancer .
    LY4101174 Antibody
  • HY-N10631
    Paucimannose

    		Endogenous Metabolite Infection Inflammation/Immunology Cancer
    Paucimannose is a mannosidic N-glycan epitope. It acts as a carcinoembryonic antigen, and a marker for cancer, stem cell properties and inflammation. Paucimannose mainly exists in plants and invertebrates. It consists of oligomannose-type N-glycans that preferentially bind to mannose-binding lectin. Paucimannose localizes on the surface of resting cells and translocates upon cell activation. It can be used in studies related to Pseudomonas aeruginosa infection, cancer and pancreatitis .
    Paucimannose
  • HY-P99109
    Zimberelimab

    GLS-010; AB-122; WBP-3055

    		 PD-1/PD-L1 Cancer
    Zimberelimab (GLS-010) is a fully human IgG4 anti-PD-1 monoclonal antibody with an EC50 of 210 pM for human PD-1. Zimberelimab effectively blocks the binding of PD-L1 and PD-L2 to cell-surface PD-1 in CHO-S cells, with IC50 values of 580 pM and 670 pM, respectively. Zimberelimab shows antitumor activities, and can be used for various cancers research, including cervical cancer, non-small cell lung cancer and classical Hodgkin’s lymphoma .
    Zimberelimab
  • HY-154927
    DSPE-PEG-Cy5

    		Liposome Cancer
    DSPE-PEG-Cy5 is a fluorescent lipophilic PEG lipid. DSPE-PEG-Cy5 can insert into cell membranes and localize uniformly on them. DSPE-PEG-Cy5 can serve as a fluorescent model molecule to optimize and validate membrane insertion conditions for cell surface functionalization. DSPE-PEG-Cy5 can be used in research on drug delivery, cancer, and other fields .
    DSPE-PEG-Cy5
  • HY-W014989
    Thioglucose

    		Biochemical Assay Reagents Cancer
    Thioglucose is a thiosugar with antioxidant properties. Thioglucose acts as an H2S/polysulfide donor to elevate intracellular sulfane sulfur levels and promote hydropersulfide formation. Thioglucose reduces the endocytosis of gold nanoparticles by phagocytes, enhances cytotoxicity and improves biocompatibility by increasing their adsorption on the surface of cancer cells. Thioglucose can be engineered into a stimulus-responsive prodrug or functional reagent for the development of targeted nanocarriers, and is used in studies related to human breast adenocarcinoma and cervical cancer .
    Thioglucose
  • HY-134061
    Arecaidine propargyl ester hydrobromide

    		Apoptosis Mitosis Cancer
    Arecaidine propargyl ester hydrobromide is an agonist of M2 muscarinic acetylcholine receptors and has the activity of inhibiting tumor cell proliferation. The application of arecaidine propargyl ester hydrobromide has shown that it can reduce the number of ovarian cancer cells in vitro and induce apoptosis and the production of reactive oxygen species (ROS) at specific concentrations. Arecaidine propargyl ester hydrobromide can also arrest cells at the G2/M phase of the cell cycle and increase the percentage of abnormal mitosis. Arecaidine propargyl ester hydrobromide is more sensitizing to ovarian surface epithelial cells with higher M2 receptor levels than to cancer cells. Arecaidine propargyl ester hydrobromide exhibits the effect of lowering arterial blood pressure when interacting with the cardiovascular system in a natural physiological state, indicating its potential pharmacological application .
    Arecaidine propargyl ester hydrobromide
  • HY-P990831
    Anti-MUC1/CD227 Antibody (C595 (NCRC48))

    		Mucin Cancer
    Anti-MUC1/CD227 Antibody (C595 (NCRC48)) is a kind of mouse IgG3 κ chimeric antibody inhibitor, targeting to human MUC1/CD227. Anti-MUC1/CD227 Antibody (C595 (NCRC48)) specifically recognizes and binds to the MUC1 protein, which is overexpressed and abnormally glycosylated on the surface of tumor cells, thereby precisely killing cancer cells. Anti-MUC1/CD227 Antibody (C595 (NCRC48)) can be used for the researches of cancer, such as ovarian cancer .
    Anti-MUC1/CD227 Antibody (C595 (NCRC48))
  • HY-P5351A
    Hyaluronan-binding peptide, biotin labeled TFA

    		Transmembrane Glycoprotein Inflammation/Immunology Cancer
    Hyaluronan-binding peptide, biotin labeled TFA is a biological active peptide. (This peptide is a hyaluronan-binding peptide biotinylated through a C-terminal GGGSK linker. Hyaluronan (HA) is a nonsulfated glycosaminoglycan expressed in the extracellular matrix and on cell surfaces. HA plays a role in fertilization, embryonic development, wound healing, angiogenesis, leukocyte trafficking to inflamed tissues, and cancer metastasis. This peptide has been shown to block HA binding to CD44 receptors and inhibit T cell proliferation.) .
    Hyaluronan-binding peptide, biotin labeled TFA
  • HY-P990833
    Anti-Mesothelin Antibody (YP218)

    		Mesothelin Cancer
    Anti-Mesothelin Antibody (YP218) is a kind of rabbit IgG chimeric antibody, targeting to human Mesothelin. Anti-Mesothelin Antibody (YP218) reacts with a epitope in the C-terminal end close to the tumor cell surface of human mesothelin (MSLN). Anti-Mesothelin Antibody (YP218) can be used for the research of cancer, such as A431/H9 tumor .
    Anti-Mesothelin Antibody (YP218)
  • HY-P990840
    Anti-GPC3 Antibody (YP7)

    		Glycoprotein VI Cancer
    Anti-GPC3 Antibody (YP7) is a kind of mouse IgG1 κ chimeric antibody, targeting to human GPC3. Anti-GPC3 Antibody (YP7) reacts with the C-lobe of cell surface-associated glypican-3 (GPC3). Anti-GPC3 Antibody (YP7) can be used for the research of cancer, such as hepatocellular carcinoma (HCC) .
    Anti-GPC3 Antibody (YP7)
  • HY-159194
    DSPE-PEG2000-Cy5.5

    		Liposome Cancer
    DSPE-PEG2000-Cy5.5 is a phospholipid-fluorophore conjugate consisting of Cy5.5 covalently linked to 1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE), serving as a surface label for liposomes in multimodal CT/optical imaging.DSPE-PEG2000-Cy5.5 can be used for the research of non-small cell lung cancer .
    DSPE-PEG2000-Cy5.5
  • HY-N10116A
    Calamenene

    		Interleukin Related IFNAR Calcium Channel Bacterial CCR Infection Cancer
    Calamenene is a sesquiterpene compound . Calamenene promotes dendritic cell maturation, upregulates CD1a, CD80, CD83, CD86, HLA-DR and CCR7 on the cell surface, reduces endocytic activity, enhances T cell-stimulating capacity, drives Th1 polarization through the secretion of IL-12, induces IFN-γ production, decreases IL-4 generation, and triggers intracellular Ca 2+ mobilization as well as dendritic cell migration towards MIP-3β. Calamenene exerts bacteriostatic and bactericidal growth-inhibitory effects against pathogenic *Vibrio harveyi*. Calamenene can be used in studies related to cancer and bacterial infections .
    Calamenene
  • HY-P991532
    AT002

    MEMD; EJ212/007-Cl2-5

    		 ALCAM/CD166 Inflammation/Immunology Cancer
    AT002 (CBAS-173, EJ212/007-Cl2-5) is a recombinant human IgG1 monoclonal antibody. AT002 targets the cell surface protein activated leukocyte adhesion molecule (ALCAM)/CD166. AT002 can be used in the research of cancer, autoimmune diseases and inflammatory diseases.
    AT002

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: